APO Research
Talk to an analyst

APO RESEARCH · REPORT

Duchenne Muscular Dystrophy

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Selected research

Industry Growth & Trends

Global Duchenne Muscular Dystrophy Industry Growth and Trends Forecast to 2032

21 December 202595 pages

Choose your research edition.

Industry ResearchDuchenne Muscular Dystrophy Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Duchenne Muscular Dystrophy Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Duchenne Muscular Dystrophy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Duchenne Muscular Dystrophy Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Duchenne Muscular Dystrophy Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.

North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.

Read the full market overview

In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

Report Scope

This report provides a structured, data-driven view of the global Duchenne Muscular Dystrophy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Duchenne Muscular Dystrophy market size, estimates, and forecasts are presented in terms of sales volume (K Doses) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Duchenne Muscular Dystrophy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Duchenne Muscular Dystrophy.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Duchenne Muscular Dystrophy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Duchenne Muscular Dystrophy Market by Company

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy Segment by Type

Exondys 51

Emflaza

Translarna

Duchenne Muscular Dystrophy Segment by Application

Hospitals

Clinics

Home Care

Duchenne Muscular Dystrophy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Duchenne Muscular Dystrophy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Exondys 51 Table 2. Major Company of Emflaza Table 3. Major Company of Translarna Table 4. Global Duchenne Muscular Dystrophy Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 6. Global Duchenne Muscular Dystrophy Sales Market Share in Volume by Type (2021-2026) Table 7. Global Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (US$ Million) Table 8. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Type (2021-2026) Table 9. Global Duchenne Muscular Dystrophy Price by Type (2021-2026) & (USD/Dose) Table 10. Global Duchenne Muscular Dystrophy Sales by Type (2027-2032) & (K Doses) Table 11. Global Duchenne Muscular Dystrophy Sales Market Share in Volume by Type (2027-2032) Table 12. Global Duchenne Muscular Dystrophy Sales by Type (2027-2032) & (US$ Million) Table 13. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Type (2027-2032) Table 14. Global Duchenne Muscular Dystrophy Price by Type (2027-2032) & (USD/Dose) Table 15. North America Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 16. North America Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 18. Europe Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 20. Asia-Pacific Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 22. Latin America Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 24. Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (US$ Million) Table 25. Duchenne Muscular Dystrophy Industry Trends Table 26. Duchenne Muscular Dystrophy Industry Drivers Table 27. Duchenne Muscular Dystrophy Industry Opportunities and Challenges Table 28. Duchenne Muscular Dystrophy Industry Restraints Table 29. Global Duchenne Muscular Dystrophy Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2021-2026) Table 31. Global Duchenne Muscular Dystrophy Sales by Company (2021-2026) & (K Doses) Table 32. Global Duchenne Muscular Dystrophy Sales Share by Company (2021-2026) Table 33. Global Duchenne Muscular Dystrophy Market Price by Company (2021-2026) & (USD/Dose) Table 34. Global Duchenne Muscular Dystrophy Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Duchenne Muscular Dystrophy Major Company Production Sites and Headquarters Table 36. Global Duchenne Muscular Dystrophy Company, Product Type & Application Table 37. Global Duchenne Muscular Dystrophy Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Duchenne Muscular Dystrophy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Duchenne Muscular Dystrophy Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Duchenne Muscular Dystrophy Sales by Region (2021-2026) & (K Doses) Table 42. Global Duchenne Muscular Dystrophy Sales Market Share in Volume by Region (2021-2026) Table 43. Global Duchenne Muscular Dystrophy Sales by Region (2021-2026) & (US$ Million) Table 44. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Region (2021-2026) Table 45. Global Duchenne Muscular Dystrophy Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 46. Global Duchenne Muscular Dystrophy Sales by Region (2027-2032) & (K Doses) Table 47. Global Duchenne Muscular Dystrophy Sales Market Share in Volume by Region (2027-2032) Table 48. Global Duchenne Muscular Dystrophy Sales by Region (2027-2032) & (US$ Million) Table 49. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Region (2027-2032) Table 50. Global Duchenne Muscular Dystrophy Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2027-2032) Table 51. Global Duchenne Muscular Dystrophy Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 53. Global Duchenne Muscular Dystrophy Sales Market Share in Volume by Application (2021-2026) Table 54. Global Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (US$ Million) Table 55. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Application (2021-2026) Table 56. Global Duchenne Muscular Dystrophy Price by Application (2021-2026) & (USD/Dose) Table 57. Global Duchenne Muscular Dystrophy Sales by Application (2027-2032) & (K Doses) Table 58. Global Duchenne Muscular Dystrophy Sales Market Share in Volume by Application (2027-2032) Table 59. Global Duchenne Muscular Dystrophy Sales by Application (2027-2032) & (US$ Million) Table 60. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Application (2027-2032) Table 61. Global Duchenne Muscular Dystrophy Price by Application (2027-2032) & (USD/Dose) Table 62. North America Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 63. North America Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 65. Europe Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 67. Asia-Pacific Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 69. Latin America Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 71. Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (US$ Million) Table 72. Sarepta Therapeutics Company Information Table 73. Sarepta Therapeutics Business Overview Table 74. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 75. Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio Table 76. Sarepta Therapeutics Recent Development Table 77. PTC Therapeutics Company Information Table 78. PTC Therapeutics Business Overview Table 79. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 80. PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio Table 81. PTC Therapeutics Recent Development Table 82. Pfizer Company Information Table 83. Pfizer Business Overview Table 84. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 85. Pfizer Duchenne Muscular Dystrophy Product Portfolio Table 86. Pfizer Recent Development Table 87. Bristol-Myers Squibb Company Information Table 88. Bristol-Myers Squibb Business Overview Table 89. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 90. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio Table 91. Bristol-Myers Squibb Recent Development Table 92. Italfarmaco Company Information Table 93. Italfarmaco Business Overview Table 94. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 95. Italfarmaco Duchenne Muscular Dystrophy Product Portfolio Table 96. Italfarmaco Recent Development Table 97. Santhera Pharmaceuticals Company Information Table 98. Santhera Pharmaceuticals Business Overview Table 99. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 100. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio Table 101. Santhera Pharmaceuticals Recent Development Table 102. North America Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country (K Doses): 2021 VS 2025 VS 2032 Table 103. North America Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 104. North America Duchenne Muscular Dystrophy Sales Market Share by Country (2021-2026) Table 105. North America Duchenne Muscular Dystrophy Sales Forecast by Country (2027-2032) & (K Doses) Table 106. North America Duchenne Muscular Dystrophy Sales Market Share Forecast by Country (2027-2032) Table 107. North America Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 108. North America Duchenne Muscular Dystrophy Market Size by Country (2021-2026) & (US$ Million) Table 109. North America Duchenne Muscular Dystrophy Market Share by Country (2021-2026) Table 110. North America Duchenne Muscular Dystrophy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 111. North America Duchenne Muscular Dystrophy Market Share Forecast by Country (2027-2032) Table 112. Europe Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country (K Doses): 2021 VS 2025 VS 2032 Table 113. Europe Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 114. Europe Duchenne Muscular Dystrophy Sales Market Share by Country (2021-2026) Table 115. Europe Duchenne Muscular Dystrophy Sales Forecast by Country (2027-2032) & (K Doses) Table 116. Europe Duchenne Muscular Dystrophy Sales Market Share Forecast by Country (2027-2032) Table 117. Europe Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 118. Europe Duchenne Muscular Dystrophy Market Size by Country (2021-2026) & (US$ Million) Table 119. Europe Duchenne Muscular Dystrophy Market Share by Country (2021-2026) Table 120. Europe Duchenne Muscular Dystrophy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 121. Europe Duchenne Muscular Dystrophy Market Share Forecast by Country (2027-2032) Table 122. Asia-Pacific Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country (K Doses): 2021 VS 2025 VS 2032 Table 123. Asia-Pacific Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 124. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share by Country (2021-2026) Table 125. Asia-Pacific Duchenne Muscular Dystrophy Sales Forecast by Country (2027-2032) & (K Doses) Table 126. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share Forecast by Country (2027-2032) Table 127. Asia-Pacific Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. Asia-Pacific Duchenne Muscular Dystrophy Market Size by Country (2021-2026) & (US$ Million) Table 129. Asia-Pacific Duchenne Muscular Dystrophy Market Share by Country (2021-2026) Table 130. Asia-Pacific Duchenne Muscular Dystrophy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. Asia-Pacific Duchenne Muscular Dystrophy Market Share Forecast by Country (2027-2032) Table 132. Latin America Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country (K Doses): 2021 VS 2025 VS 2032 Table 133. Latin America Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 134. Latin America Duchenne Muscular Dystrophy Sales Market Share by Country (2021-2026) Table 135. Latin America Duchenne Muscular Dystrophy Sales Forecast by Country (2027-2032) & (K Doses) Table 136. Latin America Duchenne Muscular Dystrophy Sales Market Share Forecast by Country (2027-2032) Table 137. Latin America Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Latin America Duchenne Muscular Dystrophy Market Size by Country (2021-2026) & (US$ Million) Table 139. Latin America Duchenne Muscular Dystrophy Market Share by Country (2021-2026) Table 140. Latin America Duchenne Muscular Dystrophy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Latin America Duchenne Muscular Dystrophy Market Share Forecast by Country (2027-2032) Table 142. Middle East and Africa Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country (K Doses): 2021 VS 2025 VS 2032 Table 143. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 144. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Country (2021-2026) Table 145. Middle East and Africa Duchenne Muscular Dystrophy Sales Forecast by Country (2027-2032) & (K Doses) Table 146. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share Forecast by Country (2027-2032) Table 147. Middle East and Africa Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Middle East and Africa Duchenne Muscular Dystrophy Market Size by Country (2021-2026) & (US$ Million) Table 149. Middle East and Africa Duchenne Muscular Dystrophy Market Share by Country (2021-2026) Table 150. Middle East and Africa Duchenne Muscular Dystrophy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Middle East and Africa Duchenne Muscular Dystrophy Market Share Forecast by Country (2027-2032) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Duchenne Muscular Dystrophy Distributors List Table 155. Duchenne Muscular Dystrophy Customers List Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Duchenne Muscular Dystrophy Image Figure 2. Global Duchenne Muscular Dystrophy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Duchenne Muscular Dystrophy Market Size (2021-2032) & (US$ Million) Figure 4. Global Duchenne Muscular Dystrophy Sales (2021-2032) & (K Doses) Figure 5. Exondys 51 Image Figure 6. Global Exondys 51 Sales YoY Growth (2021-2032) & (K Doses) Figure 7. Emflaza Image Figure 8. Global Emflaza Sales YoY Growth (2021-2032) & (K Doses) Figure 9. Translarna Image Figure 10. Global Translarna Sales YoY Growth (2021-2032) & (K Doses) Figure 11. Global Duchenne Muscular Dystrophy Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Duchenne Muscular Dystrophy Market Share by Type 2025 VS 2032 Figure 13. North America Duchenne Muscular Dystrophy Sales Market Share in Volume by Type in 2025 Figure 14. North America Duchenne Muscular Dystrophy Sales Market Share in Value by Type in 2025 Figure 15. Europe Duchenne Muscular Dystrophy Sales Market Share in Volume by Type in 2025 Figure 16. Europe Duchenne Muscular Dystrophy Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share in Value by Type in 2025 Figure 19. Latin America Duchenne Muscular Dystrophy Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Duchenne Muscular Dystrophy Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Duchenne Muscular Dystrophy Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospitals Image Figure 26. Global Hospitals Sales YoY Growth (2021-2032) & (K Doses) Figure 27. Clinics Image Figure 28. Global Clinics Sales YoY Growth (2021-2032) & (K Doses) Figure 29. Home Care Image Figure 30. Global Home Care Sales YoY Growth (2021-2032) & (K Doses) Figure 31. Global Duchenne Muscular Dystrophy Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Duchenne Muscular Dystrophy Market Share by Application 2025 VS 2032 Figure 33. North America Duchenne Muscular Dystrophy Sales Market Share in Volume by Application in 2025 Figure 34. North America Duchenne Muscular Dystrophy Sales Market Share in Value by Application in 2025 Figure 35. Europe Duchenne Muscular Dystrophy Sales Market Share in Volume by Application in 2025 Figure 36. Europe Duchenne Muscular Dystrophy Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share in Value by Application in 2025 Figure 39. Latin America Duchenne Muscular Dystrophy Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Duchenne Muscular Dystrophy Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share in Value by Application in 2025 Figure 43. North America Duchenne Muscular Dystrophy Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Figure 44. North America Duchenne Muscular Dystrophy Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Duchenne Muscular Dystrophy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Duchenne Muscular Dystrophy Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Duchenne Muscular Dystrophy Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Figure 48. Europe Duchenne Muscular Dystrophy Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Duchenne Muscular Dystrophy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Duchenne Muscular Dystrophy Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Duchenne Muscular Dystrophy Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Figure 52. Asia-Pacific Duchenne Muscular Dystrophy Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Duchenne Muscular Dystrophy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Duchenne Muscular Dystrophy Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Duchenne Muscular Dystrophy Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Figure 56. Latin America Duchenne Muscular Dystrophy Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Duchenne Muscular Dystrophy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Duchenne Muscular Dystrophy Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Figure 60. Middle East and Africa Duchenne Muscular Dystrophy Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Duchenne Muscular Dystrophy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Duchenne Muscular Dystrophy Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Duchenne Muscular Dystrophy Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Duchenne Muscular Dystrophy Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Exondys 51
  • Emflaza
  • Translarna
Applications
  • Hospitals
  • Clinics
  • Home Care
Companies covered
  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Duchenne Muscular Dystrophy Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Duchenne Muscular Dystrophy Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Duchenne Muscular Dystrophy Market by Type
  6. 1.3.1 Exondys 51
  7. 1.3.2 Emflaza
  8. 1.3.3 Translarna
  9. 1.4 Global Duchenne Muscular Dystrophy Market Size by Type
  10. 1.4.1 Global Duchenne Muscular Dystrophy Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Duchenne Muscular Dystrophy Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Duchenne Muscular Dystrophy Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Duchenne Muscular Dystrophy Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Duchenne Muscular Dystrophy Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Duchenne Muscular Dystrophy Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Duchenne Muscular Dystrophy Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Duchenne Muscular Dystrophy Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Duchenne Muscular Dystrophy Industry Trends
  2. 2.2 Duchenne Muscular Dystrophy Industry Drivers
  3. 2.3 Duchenne Muscular Dystrophy Industry Opportunities and Challenges
  4. 2.4 Duchenne Muscular Dystrophy Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Duchenne Muscular Dystrophy Revenue (2021-2026)
  2. 3.2 Global Top Players by Duchenne Muscular Dystrophy Sales (2021-2026)
  3. 3.3 Global Top Players by Duchenne Muscular Dystrophy Price (2021-2026)
  4. 3.4 Global Duchenne Muscular Dystrophy Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Duchenne Muscular Dystrophy Major Company Production Sites & Headquarters
  6. 3.6 Global Duchenne Muscular Dystrophy Company, Product Type & Application
  7. 3.7 Global Duchenne Muscular Dystrophy Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Duchenne Muscular Dystrophy Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Duchenne Muscular Dystrophy Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Duchenne Muscular Dystrophy Tier 1, Tier 2, and Tier 3
4 Duchenne Muscular Dystrophy Regional Status and Outlook
  1. 4.1 Global Duchenne Muscular Dystrophy Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Duchenne Muscular Dystrophy Historic Market Size by Region
  3. 4.2.1 Global Duchenne Muscular Dystrophy Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Duchenne Muscular Dystrophy Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Duchenne Muscular Dystrophy Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Duchenne Muscular Dystrophy Forecasted Market Size by Region
  7. 4.3.1 Global Duchenne Muscular Dystrophy Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Duchenne Muscular Dystrophy Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Duchenne Muscular Dystrophy Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Duchenne Muscular Dystrophy by Application
  1. 5.1 Duchenne Muscular Dystrophy Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Home Care
  5. 5.2 Global Duchenne Muscular Dystrophy Market Size by Application
  6. 5.2.1 Global Duchenne Muscular Dystrophy Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Duchenne Muscular Dystrophy Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Duchenne Muscular Dystrophy Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Duchenne Muscular Dystrophy Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Duchenne Muscular Dystrophy Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Duchenne Muscular Dystrophy Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Duchenne Muscular Dystrophy Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Duchenne Muscular Dystrophy Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sarepta Therapeutics
  2. 6.1.1 Sarepta Therapeutics Company Information
  3. 6.1.2 Sarepta Therapeutics Business Overview
  4. 6.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio
  6. 6.1.5 Sarepta Therapeutics Recent Developments
  7. 6.2 PTC Therapeutics
  8. 6.2.1 PTC Therapeutics Company Information
  9. 6.2.2 PTC Therapeutics Business Overview
  10. 6.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio
  12. 6.2.5 PTC Therapeutics Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Duchenne Muscular Dystrophy Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
  25. 6.5 Italfarmaco
  26. 6.5.1 Italfarmaco Company Information
  27. 6.5.2 Italfarmaco Business Overview
  28. 6.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Italfarmaco Duchenne Muscular Dystrophy Product Portfolio
  30. 6.5.5 Italfarmaco Recent Developments
  31. 6.6 Santhera Pharmaceuticals
  32. 6.6.1 Santhera Pharmaceuticals Company Information
  33. 6.6.2 Santhera Pharmaceuticals Business Overview
  34. 6.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio
  36. 6.6.5 Santhera Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Duchenne Muscular Dystrophy Sales by Country
  2. 7.1.1 North America Duchenne Muscular Dystrophy Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Duchenne Muscular Dystrophy Sales by Country (2021-2026)
  4. 7.1.3 North America Duchenne Muscular Dystrophy Sales Forecast by Country (2027-2032)
  5. 7.2 North America Duchenne Muscular Dystrophy Market Size by Country
  6. 7.2.1 North America Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Duchenne Muscular Dystrophy Market Size by Country (2021-2026)
  8. 7.2.3 North America Duchenne Muscular Dystrophy Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Duchenne Muscular Dystrophy Sales by Country
  2. 8.1.1 Europe Duchenne Muscular Dystrophy Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Duchenne Muscular Dystrophy Sales by Country (2021-2026)
  4. 8.1.3 Europe Duchenne Muscular Dystrophy Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Duchenne Muscular Dystrophy Market Size by Country
  6. 8.2.1 Europe Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Duchenne Muscular Dystrophy Market Size by Country (2021-2026)
  8. 8.2.3 Europe Duchenne Muscular Dystrophy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Duchenne Muscular Dystrophy Sales by Country
  2. 9.1.1 Asia-Pacific Duchenne Muscular Dystrophy Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Duchenne Muscular Dystrophy Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Duchenne Muscular Dystrophy Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Duchenne Muscular Dystrophy Market Size by Country
  6. 9.2.1 Asia-Pacific Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Duchenne Muscular Dystrophy Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Duchenne Muscular Dystrophy Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Duchenne Muscular Dystrophy Sales by Country
  2. 10.1.1 South America Duchenne Muscular Dystrophy Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Duchenne Muscular Dystrophy Sales by Country (2021-2026)
  4. 10.1.3 South America Duchenne Muscular Dystrophy Sales Forecast by Country (2027-2032)
  5. 10.2 South America Duchenne Muscular Dystrophy Market Size by Country
  6. 10.2.1 South America Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Duchenne Muscular Dystrophy Market Size by Country (2021-2026)
  8. 10.2.3 South America Duchenne Muscular Dystrophy Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country
  2. 11.1.1 Middle East and Africa Duchenne Muscular Dystrophy Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Duchenne Muscular Dystrophy Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Duchenne Muscular Dystrophy Market Size by Country
  6. 11.2.1 Middle East and Africa Duchenne Muscular Dystrophy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Duchenne Muscular Dystrophy Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Duchenne Muscular Dystrophy Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Duchenne Muscular Dystrophy Value Chain Analysis
  2. 12.1.1 Duchenne Muscular Dystrophy Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Duchenne Muscular Dystrophy Production Mode & Process
  7. 12.2 Duchenne Muscular Dystrophy Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Duchenne Muscular Dystrophy Distributors
  10. 12.2.3 Duchenne Muscular Dystrophy Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst